We retrospectively evaluated the predictive and prognostic role of HER2 expression in 44 metastatic breast cancer (MBC) patients treated with high-dose consolidation chemotherapy (HDCT) and autologous stem cell support after induction chemotherapy (IC) with six courses of epirubicin þ paclitaxel (22 patients) or gemcitabine þ epirubicin þ paclitaxel (22 patients). HER2 expression was evaluated by an immunohistochemical method (Herceptest, Dako). A total of 13 patients (29.5%) showed a HER2 overexpression (score 3 þ ). After IC, nine patients were in complete response (CR), 30 in partial response (PR), and five in stable disease (SD); after HDCT, 20 (45.5%) obtained a CR, and 23 were in PR, for a conversion rate of 48.5%. Conversion rate for HER2-positive patients was 87.5 vs 37% for HER2-negative patients (P ¼ 0.018). The median progressionfree (PFS) and overall survivals (OS) were 17.6 (95% CI 13.2-22.0) and 44 (95% CI 25.9-62.3) months, respectively. Patients with HER2 overexpression experienced a significantly (P ¼ 0.0042) shorter median PFS (15.3 months, 95% CI 11.1-19.5) compared to HER2-negative patients (21.3 months,). The median OS was 27.6 months (95% CI 4.5-50.7) in HER2-positive patients and 50.3 months (95% CI 38.7-62.0) in HER2-negative patients (P ¼ 0.345). These results indicate that HER2 overexpression predicts a worse outcome for patients with MBC treated with HDCT, despite the high CR rate obtained in this subset of patients.
metastatic breast cancer
Her2/neu oncogene encodes a 185 kDa transmembrane glycoprotein receptor, member of the EGFR family, which mediates a complex system of signal transduction affecting both cell proliferation and survival.
1-2 HER2 is overexpressed in 20-30% of breast cancer. This overexpression is associated with a poorer outcome and with resistance to conventional hormonal chemotherapy. [3] [4] [5] [6] [7] [8] [9] [10] On the other hand, HER2 overexpression may correlate with a better response to doxorubicin and paclitaxel. [11] [12] [13] [14] [15] [16] The efficacy of high-dose chemotherapy in metastatic breast cancer (MBC) is yet to be established. 17 Therefore, it is of interest to verify whether, among the heterogeneous MBC population, a subset of patients might benefit from more aggressive treatments. It has been postulated that high-dose chemotherapy may overcome the effect of some negative prognostic factors. Only few analyses have been conducted to evaluate the impact of HER2 expression in patients with MBC treated with high-dose chemotherapy. The majority of these studies showed a worse outcome for HER2-positive patients. [18] [19] [20] [21] [22] Overall, these studies included 274 patients with HER2 assessed on the tumor, and the patients were treated with a variety of induction regimens, not including taxanes.
We performed a retrospective analysis in MBC patients treated with high-dose chemotherapy following induction regimens including anthracyclines and taxanes. The aim of this analysis was to evaluate the relationship between HER2 status, response to high-dose chemotherapy, progression free survival (PFS), and overall survival (OS).
Methods

High-dose chemotherapy program
Overall, 66 patients have been enrolled into high-dose chemotherapy prospective trials from 1995 to 1999. A total of 22 patients were not included in this retrospective analysis because of missing tumor blocks (15 patients) or chemoresistant disease (seven patients), leaving 44 patients for this analysis. Inclusion criteria were as follows: women with histologically proven MBC with measurable disease in complete response (CR), partial response (PR) or stable disease (SD) after induction chemotherapy, age p60 years, ECOG performance status (PS) p1, adequate renal, liver, and bone marrow functions, normal cardiac function (left ventricular ejection fraction 450%), negative serological tests for hepatitis B, C, and human immunodeficency viruses. Exclusion criteria were: bone disease only, documented myocardial infarction within 6 months prior to the study entry, or a history of second or third degree A/V block or heart failure, active infections or other serious underlying medical conditions, and symptomatic brain metastases. The presence of positive bone marrow was not an exclusion criteria. Prior adjuvant chemotherapy and/or hormonal treatment was allowed. Patients were required to sign an informed consent and the protocol was approved by the local human investigation committee.
Induction chemotherapy consisted six courses of anthracycline-taxane combinations (epirubicin 90 mg/m 2 plus taxol 175 mg/m 2 i.v. day 1, 22 patients, or epirubicin 90 mg/m 2 day 1 plus gemcitabine 1000 mg/m 2 i.v. day 1, 4 plus taxol 175 mg/m 2 i.v. day 1, 22 patients) given at 3-week intervals. After the first three cycles, patients were treated with G-CSF until an absolute CD34 þ cell count X50/ml; at this time leukapheresis was performed using a Fenwall CS 3000 cell separator (Baxter, Chicago, IL, USA) or COBE Spectra. This was considered successful if at least 5 Â 10 Maximum tolerated dose of idarubicin was defined at 60 mg/m 2 . Criteria for drug delivery, stem cell storage/ reinfusion, supportive care, and results of these prospective trials have been previously described.
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Pre-treatment and on study evaluation Standard evaluations including physical examination, ECOG PS, routine hematology and biochemistry analysis, cardiac evaluation, and appropriate radiological exams to assess the extent of disease were performed in the 4 weeks prior to enrolment. Tumor response and cardiac evaluation were assessed within 2 months after high-dose chemotherapy by imaging techniques identical to those used at baseline. Tumor response was classified according to the Standard Eastern Cooperative Oncology Group criteria. 26 CR was defined as disappearance of all clinical evidence of tumor, determined by two observations not less than 4 weeks apart. PR was defined as 50% or greater decrease in the sum of the products of the largest diameter of the target lesions, determined by two observations not less than 4 weeks apart, in the absence of any new or progressive tumor lesions. SD was defined as steady state of response less than PR or progression less than progressive disease (PD) for at least 4 weeks duration and no appearance of new lesions. PD was defined as an increase of at least 25% in the product of measured lesions and/or as appearance of new lesions.
Immunohistochemical analysis (IHC)
Paraffin-embedded tumor blocks collected at the time of diagnosis were obtained from the pathology departments of the referring hospitals. Sections of 3 or 4 mm thick were deparaffinized in xylene, and rehydrated in ethanol at graded concentration (95-70% each for 371 min) at room temperature. The sections were subjected to heat-induced epitope retrieval by immersion in a citrate buffer at 95-991C for 40 min; slides were cooled for 20 min at room temperature, rinsed, and incubated with anti-endogenous peroxidase for 5 min (3% hydrogen peroxide). Sections were rinsed again, and primary rabbit HER2/neu antibody was then applied for 30 min at room temperature. At this point, sections were treated with visualization reagent, represented by a solution containing both horseradish peroxidase linked to a common dextran polymer backbone and secondary goat antirabbit antibody. Then, sections were incubated with chromogen 3-3-diaminobenzedine for 10 min and counterstained with hematoxylin for 2-5 min.
Immunostains were scored on a scale from 0 to 3 þ using the system outlined in the DAKO Herceptest: Score 0: no staining or weak staining in less than 10% of the cells; score 1 þ : faint or barely perceptible staining in more than 10% of cells or with noncircumferential staining; score 2 þ : moderate circumferential membrane staining in more than 10% of cells; score 3 þ : strong circumferential membrane staining in more than 10% of cells.
Tumor samples with score 3 þ were considered as overexpressing HER2.
Statistical methods
The association with HER2 overexpression and response to chemotherapy was evaluated using the w 2 test. PFS and OS were calculated from the start of induction chemotherapy and estimated by Kaplan-Meier life table method. 27 Comparisons of survival by HER2 status (positive: 3 þ , negative: 0-2 þ ) were conducted using the log-rank test. 28 
Results
Patient population
Patients' characteristics are reported in Table 1 . The median age was 48 years and the median ECOG PS was 0. In total, 70% of patients had visceral dominant disease. The majority of the patients had received prior adjuvant chemotherapy, which included anthracyclines in 25% of the cases. Hormonal receptors were positive in 45.5% of the cases. However, all patients had hormone refractory disease. A total of 13 patients (29.5%) showed a Herceptest score 3 þ . Five patients with HER2 score 2 þ were 
Her-2 overexpression and response to chemotherapy
After induction chemotherapy, nine patients (20.5%) showed a CR, 30 (68%) a PR, and five (11%) SD. After high-dose chemotherapy, CR was obtained in 23 (52.3%) and PR in 20 (45.5%) patients, while SD was present in only one patient (conversion rate: 48.5%) ( Table 2) .
Responses to high-dose chemotherapy were evaluated according to HER2 status in the 35 patients with less than CR after induction chemotherapy; seven out of eight (87.5%) HER2-positive patients achieved a better response after high-dose chemotherapy vs 10 out of 27 (37%) in the HER2-negative group (P ¼ 0.018). The sites of metastases were not significantly different in the two groups of patients.
Her-2 overexpression and survival times
The median PFS and OS were 17.6 (95% CI 13.2-22.0) and 44 (95% CI 25.9-62.3) months, respectively (Figure 1) .
The median PFS was significantly shorter (P ¼ 0.0042) in patients with HER2 overexpression (15.3 months, 95% CI 11.1-19.5) as compared to HER2-negative patients (21.3 months, 95% CI 14.3-28.4). The median OS was 27.6 months (95% CI 4.5-50.7) in HER2-positive patients vs 50.3 months (95% CI 38.7-62.0) in HER2-negative patients; however, this difference is not significant (P ¼ 0.345) (Figures 2 and 3) .
Overall, 2 year PFS and OS rates were 32 and 70%, respectively, in the entire population. The 2-year PFS rate was 45% in HER2-negative patients; no HER2-positive patient was progression free at that time. The 2-year OS rates were 54% in HER2-positive patients and 77% in HER2-negative patients, respectively. 
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However, since this procedure can now be considered safe and demonstrated a high level of activity, many investigators have tried to identify subsets of patients in whom the activity of HDCT can be translated into an advantage in survival.
Among disease-related factors, HER2 status is associated with a poorer survival and lower sensitivity to tamoxifen and chemotherapy with CMF, [3] [4] [5] [6] [7] [8] [9] [10] while it seems to improve sensitivity to anthracyclines and to taxanes. [11] [12] [13] [14] [15] [16] Our study demonstrates that HER2 overexpression is associated with a higher sensitivity to HDCT (conversion rate 87.5% in HER2-positive patients vs 37% in HER2-negative patients). However, this greater chemosensitivity is not translated into a positive impact on median PFS, since it was significantly shorter for HER2-positive patients (15.3 vs 21.3 months). The median overall survival also was shorter in HER2-positive patients (27.6 vs 50.3 months, P ¼ 0.345), although this difference was not statistically significant, possibly because of a small numbers of events. Moreover, since approximately 30% of HER2-positive patients received trastuzumab as salvage treatment at the time of relapse, this treatment might have improved survival.
Other studies performing similar analyses showed similar results. Bewick et al evaluated the role of HER2 circulating extracellular domain (ECD) in MBC patients treated with high-dose chemotherapy with paclitaxel containing regimen, after anthracycline-based induction chemotherapy. This analysis showed a significantly shorter PFS and OS for patients with high level of ECD as compared to those with low levels. [18] [19] Kim et al 20 reported similar results in assessing HER2 status by IHC. In contrast to our and the previously quoted studies, comparing ECD and HER2 status evaluated by IHC and FISH on primary tumors in patients treated with HD alkylating agents after anthracycline-based induction chemotherapy, Harris et al 22 concluded that ECD only can identify a subset of patients at worse prognosis, while IHC and FISH were not correlated with outcome.
In the adjuvant setting, a large randomized trial has shown that relapse-free survival was significantly improved in patients with HER2-negative tumors treated with HDCT as compared to standard chemotherapy, while no benefit was documented in HER2-positive patients. 33 In conclusion, most of available data indicate that highdose chemotherapy cannot overcome the negative prognostic impact of HER2 overexpression in MBC. Our study reinforces these observations because all the patients were treated with anthracycline-taxane combinations as induction chemotherapy and the definition of HER2 positivity was restricted to patients with Herceptest score 3 þ only.
An additional conclusion from the present study is that HER2 status can predict activity of high-dose chemotherapy, thus confirming an increased sensitivity of HER2-positive patients to more aggressive regimens including anthracyclines and taxanes. [11] [12] [13] [14] [15] [16] In conclusion, patients with MBC overexpressing HER2 are not good candidates for HDCT. However, since these patients have an increased chemosensitivity, new treatment strategies, including HDCT and HER2 targeted therapies, should be investigated. 34 HER2 and HDCT in MBC V Guarneri et al
